InMed Sets CVR Distribution Record Date for Proposed Merger
InMed has set November 5, 2026 as the record date for shareholders to receive contingent value rights tied to its merger with Mentari.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
InMed Pharmaceuticals said that the close of business on November 5, 2026 will serve as the record date for distributing contingent value rights (CVRs) to shareholders in connection with its proposed merger with Mentari Therapeutics. Under the merger agreement dated May 19, 2026, each common share will entitle its holder to one CVR.
The distribution depends on shareholder approval of the Return of Capital Proposal at the annual general and special meeting scheduled for November 4, 2026. Investors who buy shares on November 5 are not expected to be holders of record. Shareholders holding through brokerage accounts need not take any action, and Odyssey Transfer and Trust Company is the rights agent.
why it matters
The item is a procedural update in a small pharmaceutical company's merger, with limited relevance to broad markets. CVR payments depend on future events and may never be made, so the outlook remains uncertain.
market impact
InMed shares: merger timing and CVR terms shape holder interest in the stock
tags
instruments
sources
- InMed Announces CVR Distribution Record Date in Connection with Proposed Merger — newsfilecorp.com, 27 October 2026 at 00:01 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗